AI-generated analysis. Always verify with the original filing.
NewAmsterdam Pharma Company N.V. announced full year 2025 financial results, reporting $728.9 million in cash, cash equivalents and marketable securities as of December 31, 2025, revenue of $22.5 million, and net loss of $203.8 million. The company provided updates on obicetrapib regulatory approvals expected in 2H26 and ongoing Phase 3 trials.
Event Type
Disclosure
Mandatory
Variant
8-K
, including Exhibit 99.1, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act or into any fi
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 NewAmsterdam Pharma Company N.V. Press Release, dated February 18, 2026 104 Cover
| Metric | Value | Basis |
|---|---|---|
| Revenue | $22.50 | |
| Research and Development Expenses | $141.80 | |
| Selling, General and Administrative Expenses | $106.40 | |
| Net Loss | $203.80 |